Sonja Zweegman, Claudia A.M. Stege, Einar Haukas, Fredrik H. Schjesvold, Mark-David Levin, Anders Waage, Rineke B.L. Leys, Saskia K. Klein, Damian Szatkowski, Per Axelsson, Trung Hieu Do, Dorota Knut-Bojanowska, Ellen van der Spek, Asta Svirskaite, Anja Klostergaard, Morten Salomo, Celine Blimark, Paula F. Ypma, Ulf-Henrik Mellqvist, Pino J. Poddighe, Marian Stevens-Kroef, Niels W.C.J. van de Donk, Pieter Sonneveld, Markus Hansson, Bronno van der Holt, Niels Abildgaard. Ixazomib-Thalidomide-low dose dexamethasone induction followed by maintenance therapy with ixazomib or placebo in newly diagnosed multiple myeloma patients not eligible for autologous stem cell transplantation; results from the randomized phase II HOVON-126/NMSG 21.13 trial. haematol [Internet]. 2020Dec.1 [cited 2024Jul.18];105(12):2879-82. Available from: https://haematologica.org/article/view/9655